Molecular and clinical stratification of astroblastomas: Three distinct fusion-defined groups informing risk-adapted treatment strategies

Astroblastoma, MN1-altered, comprises three molecularly and clinically distinct groups, characterized by different fusion genes, including those without MN1. These new insights, including identification of potential predictive biomarkers like 14q/16q loss, provide a framework for development of risk-stratified therapeutic approaches. Importantly, we identified a molecularly defined high-risk group that benefits from radiation therapy. Our findings redefine Astroblastoma as a molecularly diverse tumor type, propose a refined classification, support the development of risk-adapted therapeutic strategies and provide a rational standard of care.